Posted by Michael Wonder on 25 Mar 2018
Ipsen receives positive CHMP opinion for Cabometyx (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma
23 March 2018 - Cabozantinib is the first and only monotherapy to demonstrate superior clinical efficacy over sunitinib in treatment-naïve patients with intermediate- or poor-risk advanced renal cell carcinoma
Ipsen announced today that the CHMP, the scientific committee of the EMA provided a positive opinion for Cabometyx (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma.
The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union.
